Last10K.com

Chinook Therapeutics, Inc. (KDNY) SEC Filing 8-K Material Event for the period ending Monday, April 10, 2023

Aduro Biotech, Inc.

HISTORY TOOLS
CIK: 1853860 Ticker: KDNY

View differences made from one to another to evaluate Aduro Biotech, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aduro Biotech, Inc..

Continue

Assess how Aduro Biotech, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aduro Biotech, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information

Material Contracts, Statements, Certifications & more

Aduro Biotech, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: KDNY
CIK: 1435049
Form Type: 8-K Corporate News
Accession Number: 0001193125-23-100603
Submitted to the SEC: Thu Apr 13 2023 4:32:00 PM EST
Accepted by the SEC: Thu Apr 13 2023
Period: Monday, April 10, 2023
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers
  2. Financial Exhibit
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/kdny/0001193125-23-100603.htm